New Challenges for HDL-Modifying Therapies as a Strategy to Lower Cardiovascular Disease Events in Statin-Treated Patients: Editorial to: “Statin-Induced Decrease in ATP-Binding Cassette Transporter A1 Expression via microRNA33 Induction may Counteract Cholesterol Efflux to High Density Lipoprotein” by E.J. Niesor et al.

Cardiovascular Drugs and Therapy

Volumn 29, Issue 1, 2015, Pages 1-3

  Rosenson, Robert S ^a   Brewer, H Bryan ^b  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b WASHINGTON HOSPITAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; CHOLESTEROL ESTER TRANSFER PROTEIN; DALCETRAPIB; HIGH DENSITY LIPOPROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PITAVASTATIN; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN; TORCETRAPIB; VERY LOW DENSITY LIPOPROTEIN; ABC TRANSPORTER A1; CHOLESTEROL; MICRORNA;

CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHROMOSOME; EDITORIAL; EVIDENCE BASED PRACTICE; HIGH RISK POPULATION; HUMAN; MACROPHAGE; MENDELIAN RANDOMIZATION ANALYSIS; PHARMACOGENOMICS; PRIORITY JOURNAL; PROTEIN POLYMORPHISM; STRATEGIC PLANNING; ANIMAL; METABOLISM;

ANIMALS; ATP BINDING CASSETTE TRANSPORTER 1; CHOLESTEROL; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LIPOPROTEINS, HDL; MICRORNAS; SIMVASTATIN;

EID: 84953342929     PISSN: 09203206     EISSN: 15737241     Source Type: Journal    
DOI: 10.1007/s10557-015-6576-7     Document Type: Editorial

References (18)

1. Rosenson RS, Brewer Jr HB, Davidson WS, et al. Cholesterol efflux and atheroprotection: advancing the concept of reverse cholesterol transport. Circulation. 2012;125:1905–19.
2. Rosenson RS, Brewer Jr HB, Chapman J, et al. HDL measures, HDL particle heterogeneity and relation to atherosclerotic cardiovascular events. Clin Chem. 2011;57:392–410.
3. Rosenson RS, Brewer Jr HB, Ansell B, et al. Translation of high-density lipoprotein function into clinical practice: current prospects and future challenges. Circulation. 2013;128:1256–67.
4. Medford R, Rosenson RS, Dagi TF, Offerman M. Biomarkers and sustainable innovation in cardiovascular drug development: lessons learned from near and far afield. Curr Atheroscler Rep. 2013;15:321–9.
5. Rosenson RS, Underberg JA. Systematic review: evaluating the effect of lipid-lowering therapy on lipoprotein and lipid value. Cardiovasc Drugs Ther. 2013;27:465–79.
6. Rosenson RS, Davidson MH, Le N-A, Burke J, Pourfazib R. Ngoc-Anh Le, Underappreciated opportunities for high-density lipoprotein particles in risk stratification and potential targets of therapy. Cardiovasc Drugs Ther. 2015;29:this issue.
7. Barter P, Gotto AM, LaRosa JC, et al. HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events. N Engl J Med. 2007;357:1301–10.
8. Voight BF, Peloso GM, Orho-Melander M, et al. Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation study. Lancet. 2012;380:572–80.
9. Rosenson RS, Davidson MH, Katheserin S, Hirsh B, Gaudet D. Triglyceride-rich lipoproteins and atherosclerosis. J Am Coll Cardiol. 2014;64:2525–40.
10. Mora S, Glynn RJ, Ridker PM. High-density lipoprotein cholesterol, size, particle number, and residual vascular risk after potent statin therapy. Circulation. 2013;128:1189–97.
11. Barter PJ, Caulfield M, Eriksson M, et al. Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med. 2007;357:2109–22.
12. Schwartz GG, Olsson AG, Abt M, et al. Effects of dalcetrapib in patients with a recent acute coronary syndrome. N Engl J Med. 2012;367:2089–99.
13. Ray KK, Ditmarsch M, Kallend D, et al. The effect of cholesteryl ester transfer protein inhibition on lipids, lipoproteins, and markers of HDL function after an acute coronary syndrome: the dal-ACUTE randomized trial. Eur Heart J. 2014;35:1792–800.
14. Niesor EF, Magg C, Ogawa N, et al. Modulating cholesteryl ester transfer protein activity maintains efficient pre-beta-HDL formation and increases reverse cholesterol transport. J Lipid Res. 2010;51:3443–54.
15. Niesor EJ, Schwartz GG, Perez A, et al. Statin-induced decrease in ATP-binding cassette transporter A1 expression via microRNA33 induction may counteract cholesterol efflux to high-density lipoprotein. Cardiovasc Drugs Ther. 2015;29: this issue.
16. Cerda A, Hirata MH, Crespo Hirata RD. Molecular mechanisms underlying statin effects on genes involved in reverse cholesterol transport. Drug Metab Drug Interact. 2012;27:101–11.
17. Rosenson RS, Otvos JD, Hsia J. Effects of rosuvastatin and atorvastatin on low-density and high-density lipoprotein particle concentrations in patients with metabolic syndrome: a randomized, double-blind, controlled study. Diabetes Care. 2009;32:1087–91.
18. van Capelleveen JC, Brewer HB, Kastelein JJ, Hovingh GK. Novel therapies focused on the high-density lipoprotein particle. Circ Res. 2014;114:193–204.